{"id":1152,"date":"2023-02-01T19:32:34","date_gmt":"2023-02-01T19:32:34","guid":{"rendered":"https:\/\/blog.trive.com\/?p=1152"},"modified":"2023-02-09T12:56:51","modified_gmt":"2023-02-09T12:56:51","slug":"gloom-for-pfizer-nyse-pfe-despite-delivering-best-revenues-ever","status":"publish","type":"post","link":"https:\/\/blog.trive.com\/de\/investition\/duster-fur-pfizer-nyse-pfe-trotz-der-lieferung-der-besten-umsatze-jemals\/","title":{"rendered":"Tr\u00fcbsinn f\u00fcr Pfizer (NYSE: PFE) trotz der besten Einnahmen aller Zeiten"},"content":{"rendered":"<p>Pfizer verzeichnete die besten Einnahmen seit einem Jahr und erzielte einen hervorragenden Umsatz von $100B, was einem deutlichen Anstieg von 23% gegen\u00fcber dem Vorjahr entspricht. Das Umsatzwachstum wurde gr\u00f6\u00dftenteils durch den Verkauf von Covid-19-Behandlungen angetrieben, von denen zwei die am meisten nachgefragten Produkte von Pfizer sind, Comirnaty (ein Covid-Impfstoff) und Paxlovid (ein antivirales Medikament).<\/p>\n\n\n\n<p>Trotz Rekordeinnahmen wird der Ausblick von Pfizer f\u00fcr 2023 durch eine \u00c4ra nach der Pandemie getr\u00fcbt, die durch r\u00fcckl\u00e4ufige Infektionen gekennzeichnet ist, was zu einer geringeren Nachfrage nach Impfstoffen f\u00fchrt. Dies spiegelt sich in Pfizers finanziellen Highlights f\u00fcr 2023 wider, mit der Erwartung eines Umsatzr\u00fcckgangs zwischen 291 TP3T und 331 TP3T auf 1 TP4T67B f\u00fcr das Jahr. Ein Umsatzr\u00fcckgang kann m\u00f6glicherweise zu einem R\u00fcckgang des Gewinns pro Aktie f\u00fchren, wodurch der Aktienkurs von Pfizer f\u00fcr 2023 in einer prek\u00e4ren Position bleibt.<\/p>\n\n\n\n<h2>Technische Analyse<\/h2>\n\n\n\n<p>Derzeit befindet sich der Preis in einem Abw\u00e4rtstrend und wird nahe den Tiefstst\u00e4nden vom Oktober 2022 gehandelt, mit Unterst\u00fctzung auf dem Niveau von $41,52. Der Widerstand bildete sich auf dem Niveau von $55, begleitet von einem starken r\u00fcckl\u00e4ufigen Momentum. Der Abw\u00e4rtstrend wurde vor allem durch niedrigere Umsatz- und Ergebniserwartungen f\u00fcr 2023 getrieben.<\/p>\n\n\n\n<p>Das besser als erwartete Gewinnergebnis sorgte f\u00fcr einen Ruck in der Kursbewegung, da die H\u00e4ndler positiv auf das Ergebnis reagierten. Unterst\u00fctzt durch die Engulfing-Kerze, die nach der Gewinnver\u00f6ffentlichung gebildet wurde, wird sich der Preis wahrscheinlich weiter nach oben bewegen, wenn bullische H\u00e4ndler mit hohen Volumina voranschreiten, mit einem potenziellen Ziel beim Widerstandsniveau von $55 pro Aktie.<\/p>\n\n\n\n<p>Wenn jedoch r\u00fcckl\u00e4ufige Anleger beim aktuellen Preis Pessimismus in Bezug auf einen d\u00fcsteren Ausblick finden, d\u00fcrfte sich der Preis wieder in Richtung Unterst\u00fctzung auf dem Niveau von $41,52 bewegen.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" loading=\"lazy\" width=\"1024\" height=\"520\" src=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-1024x520.png\" alt=\"\" class=\"wp-image-1153\" srcset=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-1024x520.png 1024w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-300x152.png 300w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-768x390.png 768w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-1536x780.png 1536w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e-18x9.png 18w, https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/PFE_2023-02-01_16-16-19_86c3e.png 1834w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2>Fundamentalanalyse<\/h2>\n\n\n\n<p>Die Covid-Impfstoffverk\u00e4ufe von $38B machten den Gro\u00dfteil der Einnahmen f\u00fcr 2023 aus. Die Verbesserung der Verk\u00e4ufe f\u00fchrte zu einem j\u00e4hrlichen Wachstum des Nettoeinkommens von 43% von $21.979B auf $31.372B. Ohne Covid-19-Behandlungen betrug das Wachstum f\u00fcr das Jahr magere 2%, was die hohe Bedeutung der pandemiebedingten Verk\u00e4ufe f\u00fcr Pfizer widerspiegelt.<\/p>\n\n\n\n<p>Die erwartete Impfung von Pfizer f\u00fcr die US-Bev\u00f6lkerung im Jahr 2023 betr\u00e4gt 24%, ein R\u00fcckgang gegen\u00fcber 31% im Jahr 2022. Dies spiegelt die schw\u00e4chere Nachfrage nach Covid-19-Behandlungen wider, da sich die Welt von der Pandemie-\u00c4ra entfernt. Dies d\u00fcrfte dem Umsatz erheblich schaden, wie sich in den Finanzkennzahlen von Pfizer widerspiegelt.<\/p>\n\n\n\n<p>Nach Diskontierung zuk\u00fcnftiger Cashflows ergibt sich ein innerer Wert von $52 je Aktie. Der aktuelle Aktienkurs wird mit einem Abschlag gehandelt und kann f\u00fcr kurzfristige Aufw\u00e4rtsbewegungen sorgen.<\/p>\n\n\n\n<h2>Zusammenfassung<\/h2>\n\n\n\n<p>Basierend auf dem errechneten inneren Wert hat Pfizer kurz- bis mittelfristig noch Luft nach oben. Die Aufw\u00e4rtsbewegung d\u00fcrfte jedoch durch r\u00fcckl\u00e4ufige Ums\u00e4tze und Gewinne f\u00fcr 2023, insbesondere in den pandemiebezogenen Segmenten, begleitet von einer m\u00f6glichen sanften Rezession, zunichte gemacht werden.<\/p>","protected":false},"excerpt":{"rendered":"<p>Pfizer posted its best revenues for a year, delivering a stellar $100B revenue, up a resounding 23% from the prior year. Revenue growth was largely driven by sales of Covid-19 treatments, two of which are Pfizer\u2019s most demanded products, Comirnaty (a covid vaccine) and Paxlovid (an antiviral drug), respectively. Despite record revenues, Pfizer\u2019s outlook for [&hellip;]<\/p>","protected":false},"author":8,"featured_media":1155,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.trive.com\/de\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog\" \/>\n<meta property=\"og:description\" content=\"Pfizer posted its best revenues for a year, delivering a stellar $100B revenue, up a resounding 23% from the prior year. Revenue growth was largely driven by sales of Covid-19 treatments, two of which are Pfizer\u2019s most demanded products, Comirnaty (a covid vaccine) and Paxlovid (an antiviral drug), respectively. Despite record revenues, Pfizer\u2019s outlook for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.trive.com\/de\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\" \/>\n<meta property=\"og:site_name\" content=\"Trive Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T19:32:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-09T12:56:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/pfizezr_en.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1022\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever\",\"datePublished\":\"2023-02-01T19:32:34+00:00\",\"dateModified\":\"2023-02-09T12:56:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"articleSection\":[\"Investment\"],\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\",\"url\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\",\"name\":\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog\",\"isPartOf\":{\"@id\":\"https:\/\/blog.trive.com\/#website\"},\"datePublished\":\"2023-02-01T19:32:34+00:00\",\"dateModified\":\"2023-02-09T12:56:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/blog.trive.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.trive.com\/#website\",\"url\":\"https:\/\/blog.trive.com\/\",\"name\":\"Trive Blog\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/blog.trive.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.trive.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/blog.trive.com\/#organization\",\"name\":\"Trive Blog\",\"url\":\"https:\/\/blog.trive.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"contentUrl\":\"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png\",\"width\":723,\"height\":199,\"caption\":\"Trive Blog\"},\"image\":{\"@id\":\"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\/\/blog.trive.com\/de\/author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.trive.com\/de\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","og_locale":"de_DE","og_type":"article","og_title":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog","og_description":"Pfizer posted its best revenues for a year, delivering a stellar $100B revenue, up a resounding 23% from the prior year. Revenue growth was largely driven by sales of Covid-19 treatments, two of which are Pfizer\u2019s most demanded products, Comirnaty (a covid vaccine) and Paxlovid (an antiviral drug), respectively. Despite record revenues, Pfizer\u2019s outlook for [&hellip;]","og_url":"https:\/\/blog.trive.com\/de\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","og_site_name":"Trive Blog","article_published_time":"2023-02-01T19:32:34+00:00","article_modified_time":"2023-02-09T12:56:51+00:00","og_image":[{"width":1022,"height":512,"url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2023\/02\/pfizezr_en.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"","Gesch\u00e4tzte Lesezeit":"3 Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#article","isPartOf":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/"},"author":{"name":"","@id":""},"headline":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever","datePublished":"2023-02-01T19:32:34+00:00","dateModified":"2023-02-09T12:56:51+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"articleSection":["Investment"],"inLanguage":"de-DE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","url":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/","name":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever - Trive Blog","isPartOf":{"@id":"https:\/\/blog.trive.com\/#website"},"datePublished":"2023-02-01T19:32:34+00:00","dateModified":"2023-02-09T12:56:51+00:00","breadcrumb":{"@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blog.trive.com\/es\/inversion\/pesimismo-para-pfizer-nyse-pfe-pese-a-obtener-los-mejores-ingresos-de-la-historia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.trive.com\/"},{"@type":"ListItem","position":2,"name":"Gloom for Pfizer (NYSE: PFE) Despite Delivering Best Revenues Ever"}]},{"@type":"WebSite","@id":"https:\/\/blog.trive.com\/#website","url":"https:\/\/blog.trive.com\/","name":"Trive Blog","description":"","publisher":{"@id":"https:\/\/blog.trive.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.trive.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/blog.trive.com\/#organization","name":"Trive Blog","url":"https:\/\/blog.trive.com\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/","url":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","contentUrl":"https:\/\/blog.trive.com\/wp-content\/uploads\/2022\/09\/cropped-cropped-trive_horizontal_black_logo.png","width":723,"height":199,"caption":"Trive Blog"},"image":{"@id":"https:\/\/blog.trive.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blog.trive.com\/de\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/1152"}],"collection":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/comments?post=1152"}],"version-history":[{"count":1,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/1152\/revisions"}],"predecessor-version":[{"id":1154,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/posts\/1152\/revisions\/1154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/media\/1155"}],"wp:attachment":[{"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/media?parent=1152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/categories?post=1152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.trive.com\/de\/wp-json\/wp\/v2\/tags?post=1152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}